FeniVate Ointment - a new solution against inflammation on the skin, ointment, 15 gr.

FeniVate is the only drug in Russia based on fluticasone propionate, the latest generation of corticosteroid for external use1,2.

It is indicated for the treatment of symptoms associated with atopic dermatitis / eczema, seborrheic or contact allergic dermatitis3,4.

Feniveite works at the cellular level thanks to the micronization technology3,4, which promotes better penetration of the active ingredient into the skin.

The drug is approved for use by adults and children over 10 years old3,4

FeniVate Ointment is a new product5 with a pronounced effect against inflammation on the skin.

FeniVate Ointment is especially suitable for use on dry or flaky affected skin surfaces4.

According to a study, FeniVate ointment helps to achieve visible improvement in skin condition in up to 90% of cases in patients with eczema6.

* New, sales start in July 2020.

1. FeniVate is the only corticosteroids for topical use based on fluticasone propionate, registered in the Russian Federation according to the State Radar Register for 2020.

2. Katsamabas AD et al. European guidelines for treatment in dermatology MedPress-Inform, 2014. 736 pages."

3. Instructions for medical use of FeniVate Cream RU P N012556 / 01 from 15.07.2009

4. Instructions for medical use of FeniVate Ointment RU P N012556 / 02 dated 16.07.2009.

5. A medicine based on fluticasone propionate (formerly Kutiveit) in the form of an ointment and cream has been available in Russia since 1995 * according to the State Radar Register for 2020.

Sales data is available from 2017 (Proxima)

6. According to the study, after applying the drug Feniveit ointment for 4 weeks in 36 out of 39 patients, doctors rated the reduction of skin manifestations as “good”, “excellent”, “clear skin” in comparison with the baseline.

Delescluse J, van der Endt JD.

A comparison of the safety, tolerability, and efficacy of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of eczema.

Cutis 1996

57: 32-38.

Name ENG

FeniVate

Clinical and pharmacological group

Topical glucocorticosteroid

ATX code

D07AC17

Structure

1 g of ointment contains: Active ingredient, mg: Fluticasone propionate (micronized) 0.05 Excipients: Propylene glycol 50.00 Sorbitan sesquioleate 5.00 Microcrystalline wax 250.00 Liquid paraffin up to 1.00 g

Indications

FeniVate, which contains the effective glucocorticosteroid fluticasone, is used in adults and children 10 years and older to relieve symptoms associated with atopic dermatitis (eczema), seborrheic dermatitis accompanied by irritation or allergic contact dermatitis.

INN / Active ingredient

Fluticasone propionate (micronized)

Specifications

Category

Antifungal

,

Psoriasis

Scope of the medicinal product

Dermatology

Manufacturer country

Poland

Minimum age from

10 years

Way of introduction

Outwardly

Brand name

FeniVate

Packaging

Box

Expiration date in days

730

The target audience

Adult

Package weight, g

twenty

Mode of application

:

Outwardly. It is indicated for adults, elderly people, children aged 10 and over. The use of the ointment is especially indicated for the treatment of dry, lichenified or scaly lesions. Apply FeniVate ointment 1 or 2 times a day in a thin layer in an amount not more than is necessary to cover the entire affected area, and rub gently 1 or 2 times a day until the effect is achieved, but not more than for 4 weeks. Allow sufficient time to absorb FeniVate ointment before applying the emollient. If the condition worsens or there is no improvement within 2 weeks, the treatment and diagnosis should be re-evaluated. When using fluticasone propionate, care should be taken to ensure that the minimum amount of therapeutic effect is applied.The resumption of the initial symptoms of dermatosis may occur when corticosteroid therapy for external use is discontinued, especially in the case of highly active drugs. Special patient groups Children 10 years and older Do not use in children under 10 years of age. Children are more likely to develop local and systemic side effects with the use of external corticosteroids, and, in general, children are recommended shorter courses of treatment and the appointment of less active drugs compared to adults. Care should be taken when using FeniVate ointment, ensuring that the drug is applied in the minimum amount for the shortest possible period of time, sufficient for the manifestation of a clinical effect.Elderly patients In clinical studies, there were no differences in the results between groups of elderly patients and younger patients. The high prevalence of reduced hepatic or renal function in elderly patients can lead to a slowdown in the elimination of the active substance from the body in the event of its systemic absorption. Thus, FeniVate ointment should be applied in a minimum amount for the shortest possible period of time, sufficient for the manifestation of a clinical effect. Patients with impaired renal and / or liver function In the case of systemic absorption (with prolonged application of the ointment over a large area), the metabolism and excretion of the active substance slow down in patients with impaired renal and / or liver function, which increases the risk of systemic toxicity. In this way,the ointment should be applied in a minimum amount for the shortest possible period of time, sufficient for the manifestation of a therapeutic effect.

"